Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarclisa. Sarclisa (isatuximab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback